Literature DB >> 3320536

Immunohistochemical distribution of the 52-kDa protein in mammary tumors: a marker associated with cell proliferation rather than with hormone responsiveness.

M Garcia1, M J Lacombe, H Duplay, V Cavailles, D Derocq, J C Delarue, B Krebs, G Contesso, H Sancho-Garnier, G Richer.   

Abstract

We have previously described a secreted glycoprotein of mol. wt 52,000 (52-kDa protein) which is induced by estrogen in some human breast cancer cell lines. This protein has been identified as the proenzyme of a lysosomal cathepsin-D-like protease which is secreted in large proportions in breast cancer cells. To determine which information may be generated by this marker when detected in mammary tumors, in comparison with hormone receptors, we used monoclonal antibodies interacting specifically with the 52-kDa protein and its related cellular processed products (mols. wts 48 and 34 kDa). A high concentration of this protein has been shown in proliferative ductal mastopathies and cysts, suggesting its value in detecting high-risk mastopathies. We now present the immunoperoxidase distribution of this protein in breast carcinoma compared to the cytosolic hormone receptors assayed in parallel. In 232 breast cancers, no correlation was found between the cellular 52-kDa protein content and cytosolic estrogen or progesterone receptor concentrations. This absence of correlation was also shown by the constitutive production of this protein by estrogen-receptor-negative breast cancer cell lines and confirmed by double immunostaining of breast cancer cell aspirates showing a dissociation between the cytoplasmic staining of this 52-kDa lysosomal protease and the nuclear staining of the estrogen receptor. These clinical results, associated with the in vitro mitogenic and proteolytic activities of this protein, strongly suggest that the 52-kDa protein staining in tissue is associated with tumor proliferation and/or invasion, rather than with hormone responsiveness.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3320536     DOI: 10.1016/0022-4731(87)90338-4

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  9 in total

Review 1.  Cathepsin D in breast cancer.

Authors:  H Rochefort
Journal:  Breast Cancer Res Treat       Date:  1990-07       Impact factor: 4.872

2.  Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods.

Authors:  U J Göhring; A Scharl; U Thelen; A Ahr; G Crombach; B R Titius
Journal:  J Clin Pathol       Date:  1996-01       Impact factor: 3.411

3.  Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive.

Authors:  W Domagala; M Markiewski; R Kubiak; J Bartkowiak; M Osborn
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

4.  Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables.

Authors:  S Veneroni; M G Daidone; G Di Fronzo; V Cappelletti; D Amadori; A Riccobon; A Paradiso; M Correale; R Silvestrini
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells.

Authors:  V Cavailles; P Augereau; M Garcia; H Rochefort
Journal:  Nucleic Acids Res       Date:  1988-03-25       Impact factor: 16.971

Review 6.  Autocrine growth factors and solid tumor malignancy.

Authors:  J H Walsh; W E Karnes; F Cuttitta; A Walker
Journal:  West J Med       Date:  1991-08

7.  Cytosol cathepsin-D content and proliferative activity of human breast cancer. The Comitato Italiano per il Controllo di Qualita del Laboratorio in Oncologia.

Authors:  A Paradiso; A Mangia; M Correale; I Abbate; G Ferri; A Piffanelli; L Catozzi; D Amadori; A Riccobon; M De Lena
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

8.  Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone and epidermal growth factor.

Authors:  G Scambia; P Benedetti; G Ferrandina; F Battaglia; G Baiocchi; S Mancuso
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

9.  Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.

Authors:  D Foucré; C Bouchet; K Hacène; N Pourreau-Schneider; A Gentile; P M Martin; A Desplaces; J Oglobine
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.